A carregar...
Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
BACKGROUND: Multiple sclerosis is one of the most prevalent neurological diseases in young adults affecting over 2 million people worldwide. Alemtuzumab is a highly effective therapy in relapsing remitting MS. Alemtuzumab is a monoclonal CD52 antibody that proved its efficacy against an active compa...
Na minha lista:
| Publicado no: | Neurol Res Pract |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7650051/ https://ncbi.nlm.nih.gov/pubmed/33324905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s42466-019-0045-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|